In a phase 3 trial involving individuals with obesity or who were overweight, the utilization of tirzepatide, which is a dual agonist targeting both GLP-1 receptors and another incretin, gastric inhibitor polypeptide (GIP), led to weight reduction of as much as 20.9% over an 18-month period [76]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.